- Net Income increased 125% to $4.3 million for the quarter ended March 31, 2021 as compared to the corresponding quarter one year ago.
- Income from Operations increased 58% to $4.1 million for the quarter ended March 31, 2021, as compared to the corresponding quarter one year ago.
- Diluted Net Income per Common Share Available to Common Stockholders increased 200% to $0.54 for the quarter ended March 31, 2021 as compared to the corresponding quarter one year ago.
- Cash and Cash Equivalents increased 11% to $40.8 million at March 31, 2021 as compared to the year-end, June 30, 2020.
- Total Revenues-Net increased 6% to $23.1 million for the quarter ended March 31, 2021, versus the corresponding quarter one year earlier.
- COVID-19 drastically affected imaging center scan volumes during this past year. However, total scan volume for quarter ended March 31, 2021 was 44,515, about the same as is was in the corresponding quarter one year ago.
- FONAR’s subsidiary HMCA now has 39 MRI scanners under its management as compared to 36 scanners one year ago.
- Net Book Value per common share increased 7% to $20.37 at March 31, 2021 as compared to the corresponding quarter one year ago.
Melville, New York–(Newsfile Corp. – May 13, 2021) – FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported today its financial results for the 3rd Fiscal Quarter and Nine Months period ended March 31, 2021. FONAR’s primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA).
Operating Results
Total Revenues-Net increased 6% to $23.1 million for the third fiscal quarter ended March 31, 2021 as compared to $21.7 million for the third fiscal quarter ended March 31, 2020. Total Revenues-Net for the nine-month period ended March 31, 2021 were $65.2 million as compared to $64.9 million for the nine-month period ended March 31, 2020.
Income from Operations increased 58% to $4.1 million for the third fiscal quarter ended March 31, 2021 as compared to $2.6 million for the third fiscal quarter ended March 31, 2020. Income from Operations for the nine-month period ended March 31, 2021 was $13.3 million as compared to $13.1 million for the nine-month period ended March 31, 2020.
Net Income increased 125% to $4.3 million for the third fiscal quarter ended March 31, 2021 as compared to $1.9 million for the third fiscal quarter ended March 31, 2020. Net Income for the nine-month period ended March 31, 2021 was $11.5 million as compared to $10.6 million for the nine-month period ended March 31, 2020.
Diluted Net Income Per Common Share Available to Common Shareholders increased 200% to $0.54 for the third fiscal quarter ended March 31, 2021 as compared to $0.18 for the third fiscal quarter ended March 31, 2020. Diluted Net Income Per Common Share Available to Common Shareholders, for the nine-month period ended March 31, 2021 increased 23% to $1.35 as compared to $1.10 for the nine-month period ended March 31, 2020.
Total Costs and Expenses were $19.0 million for the third fiscal quarter ended March 31, 2021 and March 31, 2020. Total Costs and Expenses for the nine-month period ended March 31, 2021 was $52.0 million and were $51.8 million for the nine-month period ended March 31, 2020.
Selling, general & administrative expenses (SG&A) decreased 15% to $6.1 million for the quarter ended March 31, 2021 as compared to $7.2 million for the quarter ended March 31, 2020. SG&A increased 7% to $16.8 million for the nine month period ended March 31, 2021 as compared to $15.7 million for the nine period ended March 31, 2020.
Balance Sheet Items
Total Cash and Cash Equivalents and Short Term Investments at March 31, 2021 increased 11% to $40.8 million as compared to the $36.8 million at June 30, 2020.
Total Assets at March 31, 2021 were $185.3 million as compared to $180.3 million at June 30, 2020.
Total Liabilities at March 31, 2021 were $50.5 million as compared to $54.0 million at June 30, 2020.
The ratio of Total Assets / Total Liabilities increased 10% to 3.7 at March 31, 2021 as compared to 3.3 at June 30, 2020.
Total Current Assets at March 31, 2021 were $103.6 million as compared to $95.9 million at June 30, 2020.
Total Current Liabilities at March 31, 2021 were $17.1 million as compared to $18.7 million at June 30, 2020.
Working Capital increased 12% to $86.5 million at March 31, 2021 as compared to $77.2 million at June 30, 2020.
Net Book Value per Common Share increased 7% to $20.37 at March 31, 2021 as compared to $19.10 at March 31, 2020, one year ago.
Cash Flow Item
Operating Cash Flow decreased 6% to $13.1 million for the nine month period ended March 31, 2021 as compared to $13.9 million for the nine month period ended March 31, 2020.
Significant Event
On March 9, 2021, FONAR rang the Nasdaq Stock Market Closing Bell, to celebrate the 50th birthday of MRI. Fifty years ago, in March 1971, the widely-read journal Science published “Tumor Detection by Nuclear Magnetic Resonance” by FONAR founder and chairman Dr. Raymond V. Damadian. This journal article explained Dr. Damadian’s discovery that there is a marked difference in the relaxation time of the NMR (MRI) signals between normal and cancerous tissues of the same type, as well as between different types of normal tissues.
Soon scientists around the world began repeating his experiment to learn for themselves about his discovery. They often cited his works in their own peer reviewed publications and Dr. Damadian’s publication in Science is often referred to as the beginning of MRI.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7879/83831_1b66f7a5d43a8931_001full.jpg
Dr. Damadian said, “I got my first idea for MRI in 1969, and in 1970 made the discovery that is the basis for the making of every MRI image ever produced and the foundation of the MRI industry. The discovery resulted in the generation of the pronounced pixel contrast that was deficient in traditional medical imaging technology (X-ray, CT, 4%) and was needed for adequate visualization of the body’s vital organs and assessment of their well-being. The discovery raised the pixel contrast of medical imaging, and the pronounced elaboration of image detail it generates to 131%.”
As reported in edubilla.com: “But without this discovery of the profound sensitivity of the relaxation time to different tissue types and malignant tissue THERE WOULD BE NO PICTURE AT ALL.”
Dr. Damadian’s discovery, as reported in Science 1971, soon led to the first patent application in MRI in 1972.
On July 3, 1977 Dr. Damadian, with his two post doctorate students, Lawrence Minkoff, Ph.D., and Michael Goldsmith. Ph.D., made the world’s first MRI scan on the first ever MRI scanner they built and named ‘Indomitable.’
Dr. Damadian began FONAR, the world’s first dedicated MRI Company in 1978, and the Company installed the world’s first commercial MRI in 1980.
In 1981 FONAR became a NASDAQ-listed company and 40 years later has delightedly marked the 50th anniversary of the birth of MRI by ringing the Nasdaq Stock Market Closing Bell.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7879/83831_1b66f7a5d43a8931_002full.jpg
Management Discussion
President and CEO Timothy R. Damadian commented on the performance of the Company’s management subsidiary over the past year. “As of March 31, 2021, we completed twelve full months of operation under the cloud of the COVID-19 pandemic. In the first three of those twelve months, ending June 30, 2020, total scan volume at HMCA-managed sites was down by 42% compared to what is was in the corresponding period one year earlier. In the next three months, ending September 30, 2020, we were down by 12%. In the next three months, ending December 2020, we were down by 5%. Finally, in the last three months, ending March 31, 2021, we were down only 1%. It’s been a remarkable recovery, thanks to the hard work of our management team, our site employees, and our headquarters’ staff.
“At the very end of March, we acquired a Stand-Up® MRI facility in Yonkers, New York, bringing the total number of HMCA-managed MRIs to 39. Physicians had been referring patients to this location for years, so we’ve been focused on preserving the existing business by continuing to provide the high quality service that they were accustomed to. By employing the marketing techniques and enhanced services that have made other HMCA-managed facilities successful, we expect to see substantial growth at this new location.”
Mr. Damadian concluded, “We have a very strong balance sheet. With Cash and Cash Equivalents at $40.8 million and relatively little debt, the Company’s liquidity puts us in an excellent position to expand our network of HMCA-managed facilities through acquisitions or establishing de novo sites.”
Chairman of the Board, Raymond V. Damadian, M.D., said, “It’s pleasing to see the Company continue to be profitable. Timothy has put together a highly competent management team that is doing a wonderful job. Since they took the reins in 2010, Total Revenues-Net have increased from $31.8 million in Fiscal Year 2010 to $85.6 million in Fiscal Year 2020, representing an effective annual growth rate of 10%.
Dr. Damadian remarked, “The FONAR UPRIGHT® Multi-Position™ MRI continues to be a favorite scanner among patients and physicians. This is especially true when it comes to the spine and it is our experience that the FONAR UPRIGHT® Multi-Position™ MRI will often see pathology that is missed by recumbent-only MRI scanners. On the other hand, we have not heard of a recumbent scanner that has seen pathology in the spine that is missed by the FONAR UPRIGHT® Multi-Position™ MRI. The reason for this is simple. The UPRIGHT® MRI images patients in their full weight-bearing position that enables visualization of the spine subjected to its full normal weight load. The impact of the body’s weight load on the spine’s anatomy and existing pathology is not visualized in the recumbent-only position provided by the conventional MRI.
“Unfortunately, COVID-19 has delayed our R&D progress on MRI imaging of cerebrospinal fluid (CSF) flow and its impact on neurodegenerative diseases. Our research is focused on quantifying CSF flow and the velocity at which it navigates through the head, neck and spine. We’ve been able to quantify CSF flow from asymptomatic patients to assess quantitative degree to which CSF flow impairment is responsible for his (her) symptoms and the degree to which the patient’s surgical or non-surgical CCJ treatment has restored the patient’s critical brain and central nervous system’s physiology to normal. We use the UPRIGHT® MRI to make cines (movies) of the fluid (CSF) as it flows up and down the neck, around the brain and up and down the spine. We are also hopeful that our research may lead to a new understanding of the role of CSF on neurodegenerative diseases, such as MS and Parkinson’s disease.”
Dr. Damadian concluded, “Once the COVID-19 crisis is over and the economy returns to normal, there is every reason to believe that FONAR will significantly grow and prosper.”
About FONAR
FONAR, the Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world’s first commercial MRI in 1980, and went public in 1981. FONAR’s signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often detects patient problems that other MRI scanners cannot because they are lie-down, “weightless-only” scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, “If the patient is claustrophobic in this scanner, they’ll be claustrophobic in my parking lot.” Approximately 85% of patients are scanned sitting while watching TV.
FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s neurologic system has been made possible first by FONAR’s introduction of the MRI and now by its latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.
FONAR’s primary source of income and growth is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA) www.hmca.com.
FONAR’s substantial list of patents includes recent patents for its technology enabling full upright weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the cerebrospinal fluid (CSF) of the central nervous system. FONAR’s UPRIGHT® Multi-Position™ MRI is the only scaner licensed under these patents.
UPRIGHT® and STAND-UP® are registered trademarks. The Inventor of MR Scanning™, CSP™, Multi-Position™, UPRIGHT RADIOLOGY™, The Proof is in the Picture™, pMRI™, CSF Videography™ and Dynamic™, are trademarks of FONAR Corporation.
This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.
Director of Communications
E-mail: [email protected]
www.fonar.com
The Inventor of MR Scanning™
An ISO 9001 Company
Melville, New York 11747
Phone: (631) 694-2929
Fax: (631) 390-1772
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
ASSETS
|
|
|
March 31, |
|
June 30, |
||||
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
40,809 |
|
|
$ |
36,802 |
|
|
Short term investments |
|
|
32 |
|
|
|
32 |
|
|
Accounts receivable – net |
|
|
4,308 |
|
|
|
4,313 |
|
|
Accounts receivable – related party |
|
|
42 |
|
|
|
6 |
|
|
Medical receivable – net |
|
|
17,021 |
|
|
|
16,172 |
|
|
Management and other fees receivable – net |
|
|
30,313 |
|
|
|
27,438 |
|
|
Management and other fees receivable – related medical practices – net |
|
|
7,530 |
|
|
|
6,896 |
|
|
Inventories |
|
|
1,971 |
|
|
|
1,649 |
|
|
Contract assets |
|
|
218 |
|
|
|
153 |
|
|
Income tax receivable |
|
|
– |
|
|
|
671 |
|
|
Prepaid expenses and other current assets |
|
|
1,330 |
|
|
|
1,758 |
|
|
Total Current Assets |
|
|
103,574 |
|
|
|
95,890 |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
2,790 |
|
|
|
2,730 |
|
|
Deferred income tax asset |
|
|
17,098 |
|
|
|
18,810 |
|
|
Property and equipment – net |
|
|
22,133 |
|
|
|
21,364 |
|
|
Right-of-use Asset – operating lease |
|
|
29,462 |
|
|
|
31,392 |
|
|
Right-of-use Asset – financing lease |
|
|
1,177 |
|
|
|
1,326 |
|
|
Goodwill |
|
|
4,269 |
|
|
|
3,985 |
|
|
Other intangible assets – net |
|
|
4,090 |
|
|
|
4,109 |
|
|
Other assets |
|
|
659 |
|
|
|
653 |
|
|
Total Assets |
|
$ |
185,252 |
|
|
$ |
180,259 |
|
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
March 31, |
|
June 30, |
||||
|
Current Liabilities: |
|
|
|
|
|
|
|
|
|
Current portion of long-term debt and capital leases |
|
$ |
193 |
|
|
$ |
108 |
|
|
Accounts payable |
|
|
1,776 |
|
|
|
1,965 |
|
|
Other current liabilities |
|
|
6,252 |
|
|
|
8,185 |
|
|
Unearned revenue on service contracts |
|
|
4,121 |
|
|
|
4,105 |
|
|
Unearned revenue on service contracts – related party |
|
|
28 |
|
|
|
– |
|
|
Operating lease liability – current portion |
|
|
3,482 |
|
|
|
3,370 |
|
|
Financing lease liability – current portion |
|
|
201 |
|
|
|
75 |
|
|
Customer deposits |
|
|
1,038 |
|
|
|
855 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Current Liabilities |
|
|
17,091 |
|
|
|
18,663 |
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term Liabilities: |
|
|
|
|
|
|
|
|
|
Unearned revenue on service contracts |
|
|
2,718 |
|
|
|
2,656 |
|
|
Deferred income tax liability |
|
|
234 |
|
|
|
234 |
|
|
Due to related medical practices |
|
|
93 |
|
|
|
93 |
|
|
Operating lease liability – net of current portion |
|
|
28,288 |
|
|
|
30,105 |
|
|
Financing lease liability – net of current portion |
|
|
1,099 |
|
|
|
1,251 |
|
|
Long-term debt and capital leases, less current portion |
|
|
770 |
|
|
|
865 |
|
|
Other liabilities |
|
|
164 |
|
|
|
150 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Long-Term Liabilities |
|
|
33,366 |
|
|
|
35,354 |
|
|
Total Liabilities |
|
|
50,457 |
|
|
|
54,017 |
|
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
LIABILITIES AND STOCKHOLDERS’ EQUITY (Continued)
|
STOCKHOLDERS’ EQUITY: |
|
March 31, |
|
June 30, |
||||||
|
Class A non-voting preferred stock $.0001 par value; 453 shares authorized at March 31, 2021 and June 30, 2020, 313 issued and outstanding at March 31, 2021 and June 30, 2020 |
|
$ |
– |
|
|
$ |
– |
|
||
|
Preferred stock $.001 par value; 567 shares authorized at March 31, 2021 and June 30, 2020, issued and outstanding – none |
|
|
– |
|
|
|
– |
|
||
|
Common Stock $.0001 par value; 8,500 shares authorized at March 31, 2021 and June 30, 2020, 6,566 and 6,459 issued at March 31, 2021 and June 30, 2020, 6,554 and 6,447 outstanding at March 31, 2021 and June 30, 2020 |
|
|
1 |
|
|
|
1 |
|
||
|
Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at March 31, 2021 and June 30, 2020; .146 issued and outstanding at March 31, 2021 and June 30, 2020 |
|
|
– |
|
|
|
– |
|
||
|
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at March 31, 2021 and June 30, 2020, 383 issued and outstanding at March 31, 2021 and June 30, 2020 |
|
|
– |
|
|
|
– |
|
||
|
Paid-in capital in excess of par value |
|
|
185,101 |
|
|
|
183,076 |
|
||
|
Accumulated deficit |
|
|
(46,728 |
) |
|
|
(56,215 |
) |
||
|
Treasury stock, at cost – 12 shares of common stock at March 31, 2021 and June 30, 2020 |
|
|
(675 |
) |
|
|
(675 |
) |
||
|
Total Fonar Corporation’s Stockholders’ Equity |
|
|
137,699 |
|
|
|
126,187 |
|
||
|
Noncontrolling interests |
|
|
(2,904 |
) |
|
|
55 |
|
||
|
Total Stockholders’ Equity |
|
|
134,795 |
|
|
|
126,242 |
|
||
|
Total Liabilities and Stockholders’ Equity |
|
$ |
185,252 |
|
|
$ |
180,259 |
|
||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
|
|
|
FOR THE THREE MONTHS ENDED |
||||||
|
REVENUES |
|
2021 |
|
2020 |
||||
|
Patient fee revenue – net of contractual allowances and discounts |
|
$ |
6,043 |
|
|
$ |
5,713 |
|
|
Product sales – net |
|
|
503 |
|
|
|
92 |
|
|
Service and repair fees – net |
|
|
1,914 |
|
|
|
1,942 |
|
|
Service and repair fees – related parties – net |
|
|
28 |
|
|
|
28 |
|
|
Management and other fees – net |
|
|
11,808 |
|
|
|
11,218 |
|
|
Management and other fees – related medical practices – net |
|
|
2,794 |
|
|
|
2,693 |
|
|
Total Revenues – Net |
|
|
23,090 |
|
|
|
21,686 |
|
|
COSTS AND EXPENSES |
|
|
|
|
|
|
|
|
|
Costs related to patient fee revenue |
|
|
2,828 |
|
|
|
2,840 |
|
|
Costs related to product sales |
|
|
152 |
|
|
|
235 |
|
|
Costs related to service and repair fees |
|
|
627 |
|
|
|
674 |
|
|
Costs related to service and repair fees – related parties |
|
|
9 |
|
|
|
9 |
|
|
Costs related to management and other fees |
|
|
7,073 |
|
|
|
6,004 |
|
|
Costs related to management and other fees – related medical practices |
|
|
1,746 |
|
|
|
1,550 |
|
|
Research and development |
|
|
419 |
|
|
|
535 |
|
|
Selling, general and administrative |
|
|
6,114 |
|
|
|
7,224 |
|
|
Total Costs and Expenses |
|
|
18,968 |
|
|
|
19,071 |
|
|
Income From Operations |
|
|
4,122 |
|
|
|
2,615 |
|
|
Other Income/(Expense) |
|
|
144 |
|
|
|
– |
|
|
Interest Expense |
|
|
(19 |
) |
|
|
(17 |
) |
|
Investment Income |
|
|
64 |
|
|
|
126 |
|
|
Income Before Provision for Income Taxes and Noncontrolling Interests |
|
|
4,311 |
|
|
|
2,724 |
|
|
Provision for Income Taxes |
|
|
(12 |
) |
|
|
(810 |
) |
|
Net Income |
|
|
4,299 |
|
|
|
1,914 |
|
|
Net Income – Noncontrolling Interests |
|
|
(431 |
) |
|
|
(653 |
) |
|
Net Income – Attributable to FONAR |
|
$ |
3,868 |
|
|
$ |
1,261 |
|
|
Net Income Available to Common Stockholders |
|
$ |
3,634 |
|
|
$ |
1,184 |
|
|
Net Income Available to Class A Non-Voting Preferred Stockholders |
|
$ |
174 |
|
|
$ |
57 |
|
|
Net Income Available to Class C Common Stockholders |
|
$ |
60 |
|
|
$ |
20 |
|
|
Basic Net Income Per Common Share Available to Common Stockholders |
|
$ |
0.55 |
|
|
$ |
0.18 |
|
|
Diluted Net Income Per Common Share Available to Common Stockholders |
|
$ |
0.54 |
|
|
$ |
0.18 |
|
|
Basic and Diluted Income Per Share – Class C Common |
|
$ |
0.16 |
|
|
$ |
0.05 |
|
|
Weighted Average Basic Shares Outstanding – Common Stockholders |
|
|
6,554 |
|
|
|
6,447 |
|
|
Weighted Average Diluted Shares Outstanding – Common Stockholders |
|
|
6,682 |
|
|
|
6,575 |
|
|
Weighted Average Basic and Diluted Shares Outstanding – Class C Common |
|
|
383 |
|
|
|
383 |
|
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
|
|
|
FOR THE NINE MONTHS |
||||||
|
REVENUES |
|
2021 |
|
2020 |
||||
|
Patient fee revenue – net of contractual allowances and discounts |
|
$ |
16,372 |
|
|
$ |
17,754 |
|
|
Product sales – net |
|
|
534 |
|
|
|
288 |
|
|
Service and repair fees – net |
|
|
5,702 |
|
|
|
6,044 |
|
|
Service and repair fees – related parties – net |
|
|
83 |
|
|
|
83 |
|
|
Management and other fees – net |
|
|
34,362 |
|
|
|
33,242 |
|
|
Management and other fees – related medical practices – net |
|
|
8,181 |
|
|
|
7,473 |
|
|
Total Revenues – Net |
|
|
65,234 |
|
|
|
64,884 |
|
|
COSTS AND EXPENSES |
|
|
|
|
|
|
|
|
|
Costs related to patient fee revenue |
|
|
7,997 |
|
|
|
8,660 |
|
|
Costs related to product sales |
|
|
477 |
|
|
|
685 |
|
|
Costs related to service and repair fees |
|
|
1,861 |
|
|
|
2,196 |
|
|
Costs related to service and repair fees – related parties |
|
|
27 |
|
|
|
30 |
|
|
Costs related to management and other fees |
|
|
18,861 |
|
|
|
18,203 |
|
|
Costs related to management and other fees – related medical practices |
|
|
4,696 |
|
|
|
4,707 |
|
|
Research and development |
|
|
1,243 |
|
|
|
1,590 |
|
|
Selling, general and administrative |
|
|
16,818 |
|
|
|
15,691 |
|
|
Total Costs and Expenses |
|
|
51,980 |
|
|
|
51,762 |
|
|
Income From Operations |
|
|
13,254 |
|
|
|
13,122 |
|
|
Other Income/(Expense) |
|
|
4 |
|
|
|
1 |
|
|
Interest Expense |
|
|
(57 |
) |
|
|
(57 |
) |
|
Investment Income |
|
|
251 |
|
|
|
413 |
|
|
Income Before Provision for Income Taxes and Noncontrolling Interests |
|
|
13,452 |
|
|
|
13,479 |
|
|
Provision for Income Taxes |
|
|
(1,974 |
) |
|
|
(2,849 |
) |
|
Net Income |
|
|
11,478 |
|
|
|
10,630 |
|
|
Net Income – Noncontrolling Interests |
|
|
(1,991 |
) |
|
|
(2,966 |
) |
|
Net Income – Attributable to FONAR |
|
$ |
9,487 |
|
|
$ |
7,664 |
|
|
Net Income Available to Common Stockholders |
|
$ |
8,915 |
|
|
$ |
7,194 |
|
|
Net Income Available to Class A Non-Voting Preferred Stockholders |
|
$ |
426 |
|
|
$ |
350 |
|
|
Net Income Available to Class C Common Stockholders |
|
$ |
146 |
|
|
$ |
120 |
|
|
Basic Net Income Per Common Share Available to Common Stockholders |
|
$ |
1.37 |
|
|
$ |
1.12 |
|
|
Diluted Net Income Per Common Share Available to Common Stockholders |
|
$ |
1.35 |
|
|
$ |
1.10 |
|
|
Basic and Diluted Income Per Share – Class C Common |
|
$ |
0.38 |
|
|
$ |
0.31 |
|
|
Weighted Average Basic Shares Outstanding – Common Stockholders |
|
|
6,489 |
|
|
|
6,442 |
|
|
Weighted Average Diluted Shares Outstanding – Common Stockholders |
|
|
6,617 |
|
|
|
6,570 |
|
|
Weighted Average Basic and Diluted Shares Outstanding – Class C Common |
|
|
383 |
|
|
|
383 |
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
|
|
|
FOR THE NINE MONTHS ENDED MARCH 31, |
||||||
|
|
|
2021 |
|
2020 |
||||
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
11,478 |
|
|
$ |
10,630 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
3,100 |
|
|
|
3,001 |
|
|
Amortization on right-of-use assets |
|
|
1,543 |
|
|
|
2,505 |
|
|
Provision(Recovery) for bad debts |
|
|
5,103 |
|
|
|
1,711 |
|
|
Deferred income tax – net |
|
|
1,712 |
|
|
|
2,481 |
|
|
Compensatory element of stock issuances |
|
|
83 |
|
|
|
– |
|
|
Stock issued for costs and expenses |
|
|
1,941 |
|
|
|
1,990 |
|
|
Abandoned patents |
|
|
1 |
|
|
|
– |
|
|
(Increase) decrease in operating assets, net: |
|
|
|
|
|
|
|
|
|
Accounts, medical and management fee receivables |
|
|
(9,551 |
) |
|
|
(6,808 |
) |
|
Notes receivable |
|
|
36 |
|
|
|
22 |
|
|
Contract assets |
|
|
(65 |
) |
|
|
372 |
|
|
Inventories |
|
|
(323 |
) |
|
|
23 |
|
|
Income tax receivable |
|
|
671 |
|
|
|
– |
|
|
Prepaid expenses and other current assets |
|
|
424 |
|
|
|
570 |
|
|
Other assets |
|
|
(1 |
) |
|
|
(142 |
) |
|
Increase (decrease) in operating liabilities, net: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
|
(189 |
) |
|
|
(175 |
) |
|
Other current liabilities |
|
|
(1,827 |
) |
|
|
(193 |
) |
|
Operating lease liabilities |
|
|
(1,168 |
) |
|
|
(2,216 |
) |
|
Financing lease liabilities |
|
|
(25 |
) |
|
|
– |
|
|
Customer deposits |
|
|
183 |
|
|
|
56 |
|
|
Other liabilities |
|
|
14 |
|
|
|
105 |
|
|
Net cash provided by operating activities |
|
|
13,140 |
|
|
|
13,932 |
|
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(2,942 |
) |
|
|
(6,601 |
) |
|
Purchase of imaging facility |
|
|
(1,123 |
) |
|
|
– |
|
|
Proceeds of short term investment |
|
|
– |
|
|
|
15,063 |
|
|
Cost of patents |
|
|
(108 |
) |
|
|
(79 |
) |
|
Net cash (used)/provided by in investing activities |
|
|
(4,173 |
) |
|
|
8,383 |
|
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
|
Repayment of borrowings and capital lease obligations |
|
|
(73 |
) |
|
|
(33 |
) |
|
Proceeds from debt |
|
|
63 |
|
|
|
– |
|
|
Distributions to noncontrolling interests |
|
|
(4,950 |
) |
|
|
(5,145 |
) |
|
Net cash used in financing activities |
|
|
(4,960 |
) |
|
|
(5,178 |
) |
|
Net Increase in Cash and Cash Equivalents |
|
|
4,007 |
|
|
|
17,137 |
|
|
Cash and Cash Equivalents – Beginning of Period |
|
|
36,802 |
|
|
|
13,882 |
|
|
Cash and Cash Equivalents – End of Period |
|
$ |
40,809 |
|
|
$ |
31,019 |
|
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83831